US comes up with two mandatory IRP use pricing models under Trump’s MFN strategy
Just before Christmas 2025, the US Centers for Medicare and Medicaid Services (CMS) unveiled two pricing models based on the…
Pricing and Market Access
China releases 2025 NRDL and first commercial insurance drug list
Win for pharma in UK – zero US tariffs, VPAG rate cap and NICE threshold increase
Slow progress as rare disease regulations in developing ASEAN states begin to take shape
Sri Lanka’s drug pricing reform: balancing affordability with sustainability
The threshold debate in Norway
Trump administration announces MFN drug pricing deal with Pfizer
Orphan drug landscape in the 7MM: launch patterns, market trends, and HTA insights
